Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia

NCT01104766 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT01104766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01104766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia
Lead sponsor
Forest Laboratories
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2010
Completion date
December 20, 2011
Enrollment
617 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia